Nanosystems L.l.c.

Eastman-kodak Company

Sterling Winthrop Inc.

Elan Pharma International Limited

Eastman Kodak

Pramod P Sarpotdar

Gary G Liversidge

Kathleen J Illig

Stephen B Ruddy

W Mark Eickhoff

Elaine Liversidge

Kenneth C Cundy

Brian D Doty

Philip Conzentino, Jr

Nats Rajagopalan

Evan Gustow

Tammy B Strassburg

Joseph A Bruno

Particulate crystalline therapeutic substances are formulated with stabilizers to enhance contact between the crystalline therapeutic substances and the mucosal membranes to provide extended therapeutic effect.

Methods for targeting drug delivery to the upper and/or lower gastrointestinal tract

Nanoparticulate crystalline x-ray contrast agents are formulated with stabilizers to enhance contact between the crystalline x-ray contrast agents and the gastrointestinal tract. Nanoparticulate crystalline therapeutic substances also formulated with stabilizers to enhance contact between the crystalline therapeutic substances and the gastrointestinal tract and to provide extended therapeutic effect.

Formulations of oral gastrointestinal diagnostic x-ray contrast agents

Dispersible particles consisting essentially of a crystalline NSAID having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 400 nm. Pharmaceutical compositions containing the particles exhibit reduced gastric irritation following oral administration and/or hastened onset of action.

Surface modified NSAID nanoparticles

A method of preparing particles of a drug substance or diagnostic imaging agent which comprises grinding the drug substance or imaging agent in the presence of grinding media comprising a polymeric resin. The method provides particles exhibiting reduced contamination.

Method of grinding pharmaceutical substances

Dispersible particles consisting essentially of a crystalline anticancer agent having a surface modifier adsorbed on the surface thereof in an amount sufficient to maintain an effective average particle size of less than about 1000 nm. Anticancer compositions comprising the particles exhibit reduced toxicity and/or enhanced efficacy, and can be administered by IV bolus injection.

Surface modified anticancer nanoparticles

This invention discloses a composition comprised of nanoparticles having p-isononylphenoxypoly (glycidol) as a surface modifier adsorbed on the surface thereof. In preferred embodiments, the p-isononylphenoxypoly (glycidol) provides resistance to particle aggregation during heat sterilization. In another preferred embodiment, those nanoparticles also comprise a stability enhancing compound. A preferred stability enhancing compound is albumin. This invention further discloses a method of making nanoparticles having p-isononylphenoxypoly(glycidol) as a surface modifier adsorbed on the surface, comprised of contacting said nanoparticles with p-isononylphenoxypoly(glycidol) for a time and under conditions sufficient to form a p-isononylphenoxypoly(glycidol) surface modified nanoparticle. In a preferred embodiment, the p-isononylphenoxypoly (glycidol) surface modified nanoparticle is further contacted with a stability enhancing compound for a time and under conditions sufficient to form a p-isononylphenoxypoly(glycidol) surface modified nanoparticle with a stability enhancing compound associated therewith.

Formulations comprising olin 10-G to prevent particle aggregation and

A unique combination of isopropyl and isobutyl alcohols synergistically increases the permeability of the skin to steroid drugs.

Growing community of inventors

Malvern, PA, United States of America

Pramod P Sarpotdar